Towards the design of Cyclooxygenase (COX) inhibitors based on 4′,5 di-substituted biphenyl acetic acid molecules: a QSAR study with a new DFT based descriptor - nucleus independent chemical shift
- 188 Downloads
Cyclooxygenase (COX) is a well-known enzyme, which converts arachidonic acid to prostaglandins H2 (PGH2), which are the effective mediators of inflammation. 4′, 5 di-substituted 3-biphenyl acetic acids (BPA) and several α-methyl derivatives (MBPA) of it are widely used as powerful nonsteroidal anti-inflammatory and analgesic agents. We have chosen these activity data because the relation between the substituents and activity is not obvious and is hard to explain and also to show the superiority of DFT method. From the DFT results, various quantum chemical based descriptors were computed but the QSAR results showed that the descriptors based on frontier electron density and a new DFT based quantum chemical descriptor, nucleus independent chemical shift (NICS) are likely to be responsible for the in vitro inhibiting activity of BPA and MPBA. It has been proposed that NICS accounts for π…π interaction and indeed leads to a better result. To the best of our knowledge, this is the first use of NICS as a descriptor to get a better relationship to facilitate the design of COX inhibitors with potentially higher biological activity.
KeywordsCOX-inhibition DFT-QSAR Frontier electron density NICS NSAID π…π interaction
We gratefully acknowledge “Jadavpur University mobile computing center” under the University Grant Commission scheme of University with potential of excellence for computation facility.
- 25.Parr RG, Yang WR (1989) Density functional theory of atoms and molecules. Oxford Univ Press, OxfordGoogle Scholar
- 26.Sanderson RT (1976) Chemical bonds and bond energy. Academic, New YorkGoogle Scholar
- 27.Sanderson RT (1961) Polar Covalence. Academic, New YorkGoogle Scholar
- 32.Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Millam MA, Daniels AD, Kudin KN, Strain MC, Farkas O, Tomasi Barone JV, Cossi M, Cammi R, Mennucci B, Pomelli C, Adamo C, Clifford S, Ochterski J, Petersson GA, Ayala PY, Cui Q, Morokuma K, Salvador P, Dannenberg JJ, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Cioslowski J, Ortiz JV, Baboul AG, Sefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Gomperts R, Martin RL, Fox DJ, Keith T, A-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Andes JL, Gonzalez C, Head-Gordon M, Replogle ES, Pople JA (2003) Gaussian 03 - Revision B.03. Gaussian Inc, Pittsburgh PAGoogle Scholar
- 34.Hawkins DM, Basak SC, Mills D (2003) J Chem Inf Comput Sci 43:579–586Google Scholar
- 35.Thomas BF, Compton DR, Martin BR, Semus SF (1991) Mol Pharmacol 40:656–665Google Scholar